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Abstract
Serial prostate-specific antigen (PSA) measurements (PSA velocity) as an
additional instrument to detect prostatic cancer was introduced in 1992. It has
previously been reported that PSA increase per year differed in the last 5 years
prior to diagnosis in patients with benign prostatic hyperplasia (0.18 ng/ml/
year), locally confined (0.75 ng/ml/year) and metastasized (4.4 ng/ml/year)
cancer of the prostate (CaP) in contrast to healthy men (0.04 ng/ml/year). The
ability of PSA velocity to detect organ-confined CaP in patients with interme-
diate PSA serum values depends therefore on a reliable and reproducible PSA
result. The present study comprised 85 men with PSA values between 3 and
8 ng/ml (Abbott IMx). PSA measurements were repeated with Abbott IMx
(n = 85 patients) and Hybritech Tandem-E (n = 59 patients) assays. The PSA
serum values differed from one examination to the other from 0.02 to 2.74 ng/
ml with the Abbott IMx. Standard deviation amounted to 0.35 ng/ml with the
Abbott IMx PSA assay. Using the Hybritech Tandem-E assay, mean standard
deviation was 1.15 ng/ml and therefore higher than with the Abbott IMx
assay. The difference from one test to the other ranged from 0.05 to 4.05 ng/ml
with the Hybritech Tandem-E. Using the Abbott IMx assay, 10.6% of all
repeat measurements exceeded 1 ng/ml whereas in the Hybritech Tandem-E
assay 62.7% of the second measurements differed 11 ng/ml from the first PSA
result. An increase in PSA serum values may therefore be due to intratest
variation, physiological day-to-day variation as well as prostatic disease. It is
important to notice that the intra-assay variation may be greater than the PSA
increase per year in a patient with CaP. Therefore, PSA velocity seems to be of
limited value.
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Introduction
Within the last 10 years, prostate specific antigen
(PSA) has been shown to be the most important tumor
marker for the diagnosis of carcinoma of the prostate
(CaP). Catalona et al. [1] could show that in the recogni-
tion of CaP, PSA determination is superior to the rectal
palpation of the prostatic gland. PSA screening particu-
larly increased the discovery of more organ-confined and
thus curable tumors compared to digital rectal examina-
tion (DRE). Especially in patients with an unsuspicious
finding on DRE, PSA elevation alone may indicate the
Range, ng/ml
26 Urol Int 1998;60:25–27 Manseck/Pilarsky/Froschermaier/
Menschikowski/Wirth
Table 1. Intermediate PSA values and
results of control measurements obtained
with two different PSA test systems from
the same serum sample
PSA Abbott IMx
1 2
Hybritech Tandem-E
3 4
3–8 2.86–10.49 1.46–15.69 0.71–11.2
Minimal difference, ng/ml – 0.02 – 0.05
Maximal difference, ng/ml – 2.74 – 4.05
Standard deviation, ng/ml 0.35 1.15
presence of a significant but – in the majority of cases –
organ-confined tumor mass [2].
However, there is no cutoff level to differentiate be-
tween healthy men and patients with benign prostatic
hyperplasia (BPH) or CaP. At intermediate PSA serum
levels (between 4 and 10 ng/ml), the risk of having CaP is
20.2–27%, and 58.1–67% at serum PSA levels exceeding
10 ng/ml [1, 3]. With the intermediate PSA range, predic-
tion of the presence of CaP is particularly difficult as
serum PSA levels overlap in patients with BPH and CaP.
Furthermore, PSA concentration was shown to be age
dependent, and in 1993 Oesterling et al. [4] were able to
establish age-specific PSA reference ranges for healthy
men on a community-based population.
Searching for an additional instrument to distinguish
between BPH and CaP, Carter et al. [5] introduced serial
PSA measurements (so-called PSA velocity). They evalu-
ated serum PSA levels of patients with histologically prov-
en BPH or CaP over an 8- to 26-year period prior to diag-
nosis. As a result of their studies, they could demonstrate
differences in PSA increases per year for healthy men,
patients with BPH as well as local or metastasized CaP.
Physiological annual PSA increase for healthy 60-year-old
patients was calculated to be 0.04 ng/ml/year. In contrast
to healthy men, in patients with BPH or locally confined
CaP the increase in PSA can be estimated to be 0.18 and
0.75 ng/ml/year, respectively. Carter et al. [5] concluded
that prostate disease is the factor most affecting serum
PSA levels with age. The following study was therefore
designed to test the ability of PSA velocity to diagnose
CaP in patients with intermediate PSA levels (between 3
and 8 ng/ml) regarding standard deviation of different
PSA assays.
Patients and Methods
85 men were included in the study. Patients’ age ranged from 30
and 87 years (mean 65.9 years). There were 14 healthy men, 57
patients with histologically proven BPH and 14 patients with histo-
logically proven CaP. In all cases, blood samples were obtained prior
to DRE and any form of treatment. All patients had serum PSA lev-
els between 3 and 8 ng/ml in the first measurement (Abbott IMx).
Using the same serum sample, PSA measurements were repeated in
85 patients with the Abbott IMx and in 59 patients with the Hybri-
tech Tandem-E assay.
Results
Serum PSA levels ranged from 3 to 8 ng/ml in the first
Abbott IMx and from 2.86 to 10.49 ng/ml in the second
evaluation (table 1). Processing of the same serum sam-
ples with the Hybritech Tandem-E resulted in 59 of the
85 patients in serum PSA levels of 1.46–15.69 ng/ml in
the first measurement and 0.71 and 11.2 ng/ml in the sec-
ond test, respectively. Standard deviation amounted to
0.35 ng/ml with the Abbott IMx PSA assay. The serum
PSA value differed between both examinations by 0.02–
2.74 ng/ml. In the Hybritech Tandem-E assay, mean stan-
dard deviation was 1.15 ng/ml and therefore higher than
in the Abbott IMx assay. The intertest difference ranged
from 0.05 to 4.05 ng/ml. 10.6% of all serum PSA repeat
measurements with the Abbott IMx assay exceeded 1 ng/
ml whereas in the Hybritech Tandem-E assay 62.7% of
the second measurements differed 11 ng/ml compared to
the first PSA result. In 83 of the 85 patients, serum PSA
values were higher with the Hybritech Tandem-E than
with the Abbott IMx. Hybritech Tandem-E PSA values
exceeded Abbott IMx results on average by 2.08 ng/ml.
Discussion
The probability of recognizing organ-confined and
thus curable CaP is highest in patients with serum PSA
values !10 ng/ml. In patients with PSA results 110 ng/
ml, the risk of having an advanced tumor with tumor
extension beyond the prostatic capsule or positive lymph
nodes increases to 34.9 and 41.3% [6]. PSA values
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!10 ng/ml are therefore especially interesting for the de-
tection of curable CaP. At unsuspicious DRE findings and
a PSA value within the normal age-specific PSA range,
there is no necessity to perform prostate biopsy except
that an abnormal PSA increase over time is recorded.
Indication for prostatic biopsy depends therefore on reli-
able and reproducible PSA measurements. As the
aforementioned results demonstrate, a PSA difference of
up to 2.74 ng/ml with the Abbott IMx PSA assay and
4.05 ng/ml with the Hybritech Tandem-E assay may be
present in the same serum sample. In addition, it must be
kept in mind that a physiological day-to-day variation
exists for PSA. Stamey et al. [7] repeated serum PSA mea-
surement in 91 patients within an interval of 38 days with
the Hybritech Tandem-R assay. The first PSA value
ranged from 4 to 10 ng/ml. They concluded that a PSA
increase is not significant as it does not exceed 30% of the
original value. Stamey et al. [7] judged this PSA difference
as physiological PSA difference from day to day. How-
ever, they did not take into consideration the intratest
variation that is even admitted by test manufacturers. For
the Abbott IMx PSA assay at a given PSA concentration
of 4 ng/ml, the PSA value may range from 3 to 5 ng/ml in
further examinations. Thus, part of the described ‘physio-
logical’ PSA range from day to day described by Stamey et
al. [7] may be due to intratest variation.
Regarding the study by Carter et al. [5] who could show
a PSA velocity of 0.04 ng/ml/year in healthy 60-year-old
men [1], it has to be considered that a PSA elevation of
1 ng/ml/year may be due to CaP on the one hand and to
the PSA intratest variation on the other hand.
Furthermore, PSA results from different test systems
cannot be directly compared. Therefore, standardization
of PSA assays is warranted.
Conclusions
PSA velocity depends on reproducible PSA measure-
ments. Our results indicate the limited reproducibility in
the same serum sample. Therefore, differences in PSA
values may be due to test variation, physiological day-to-
day variation as well as prostatic disease. In addition, the
determination of PSA velocity requires more than two
measurements. In case of an increased PSA value, control
measurements should be performed to ascertain a real
PSA increase. In the intermediate PSA range, changes in
this tumor marker have to be regarded very carefully.
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